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Abstract
Background: Radiation therapy (RT) of bone metastases provides an important treatment approach in palliative
care treatment concepts. As a consequence of treatment, the extent of radiation-induced toxicity is a crucial feature
with consequences to a patient’s quality of life. In this context this study aims at reducing the extent of radiation-
induced side effects and toxicity by assuming a better sparing of normal tissue with the use of intensity-modulated
instead of conventionally delivered external beam radiotherapy.
Methods/design: In this prospective, randomized, single-center trial for patients with spinal bone metastases, RT is
performed as either image-guided intensity-modulated radiotherapy (10x3Gy) or conventionally fractionated
external beam radiotherapy (10x3Gy). Afterwards radiation-induced toxicity will be assessed and compared 3 and 6
months after the end of radiation.
Discussion: The aim of this pilot study is the evaluation of achievable benefits, with reduced radiation
toxicity being the primary endpoint in the comparison of intensity-modulated radiotherapy versus
conventional radiotherapy for patients with spinal bone metastases. Secondarily, bone re-calcification, quality
of life, pain relief, spinal instability, and local control will be measured and compared between the two
treatment groups.
Trial registration: ClinicalTrials.gov, NCT02832830. Registered on 12 July 2016.
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Background
Secondary bone metastases in patients with cancer are
most often located in the vertebral spine [1–4], leading to
complications such as bone fractures, neurological impair-
ment, and especially pain [5–10]. Radiation therapy of
bone metastases as a palliative oncological treatment con-
cept is supposed to prevent and treat symptoms such as
fatigue and pain. As a consequence of treatment, the ex-
tent of radiation-induced toxicity should be kept as low as
possible, as it may also immensely reduce the patients’
quality of life.
Conventionally fractionated external beam radiotherapy
is one of the most important radiotherapeutic treatment
options for spinal bone metastases, delivering common
doses of 30 Gy and resulting in a significant decrease in
pain [11]. Nevertheless, the use of this technique is limited
due to unsatisfactory sparing of surrounding normal
tissue as well as application of high doses to organs at
risk such as the spinal cord. As the spinal cord is cen-
trally localized within the vertebral body and thus in
the target volume, even modern techniques will never
be able to completely spare this at-risk organ. However,
every reduction of the dose delivered to nearby tissue
still can lead to a decrease of side effects and thus a
higher quality of life. The use of intensity-modulated
radiotherapy aims to better spare the surrounding tissue,
leading to a reduction of possible radiation-induced side
effects [12]. Image,guidance additionally matches the pa-
tient’s positioning to the treatment field and thus im-
proves the accuracy of dose distribution [13].
Considering the extent of radiation-induced acute and
late side effects as well as toxicity with its contribution to
reduced quality of life, this randomized study compares
the quantitative amount of toxicity by using the two
above-mentioned radiotherapeutic treatment concepts.
Methods/design
Recruitment and study design
This prospective, single-center pilot study is performed
at the Department of Radiation Oncology at the Univer-
sity Hospital of Heidelberg for patients with spinal bone
metastases with indication for radiotherapy. As shown in
Fig. 1, participants will be randomized into two groups:
one group receiving intensity-modulated radiotherapy
treatment (group A) and the other conventional external
beam radiotherapy (group B).
The Standard Protocol Items: Recommendations for
Interventional Trials (SPIRIT) 2013 checklist shows the
study guidelines in more detail (see Additional file 1).
Before the start of radiotherapy, the recruitment of eli-
gible participants firstly includes the explanation, to each
potential study participant, of the purpose, implementa-
tion, design, aims, requirements, and timeline of this
study as well as the description of the two different radi-
ation techniques and common ethical issues.
Inclusion criteria
Patients will be included who:
– Have metastases in the vertebral spine, regardless of
number of metastases
– Have an indication for radiation therapy, such as
bone pain, spinal instability, and neurological deficit
– Are aged 18 to 85
– Have Karnofsky performance status ≥50
– Have signed a Declaration of Informed Consent
Exclusion criteria
Patients will be excluded who:
– Have bony lesions caused by multiple myeloma or
lymphoma
– Have severe neurological and psychiatric
impairment
– Have undergone previous radiation therapy with
overlapping areas
Drop-out criteria
Criteria that will lead to the drop-out of a patient before
completion of this study may be any kind of treatment
for medical reasons or impairment that will result in an
interruption or early completion of radiotherapy.
Furthermore, the patient’s desire to exit the study or
withdrawal of consent as well as any unexpected serious
Fig. 1 Timeline for IRON-1. RT radiotherapy, IMRT intensity-modulated radiotherapy
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adverse event (SAE) occurring during treatment or in
follow-up that leads to early completion of the study will
result in drop-out.
Radiotherapeutic planning and treatment implementation
All patients receive a planning computed tomography
(CT) scan with a slice thickness of 3–5 mm. Patient po-
sitioning depends on the area being treated and includes
the use of various fixation devices, such as Wingstep®
and Prostep® (Elekta, Stockholm, Sweden) for lesions in
the thoracic or lumbar spine as well as head holders
such as Aquaplast masks (Aquaplast Corporation,
Wyckoff, NJ, USA) for cervical spine immobilization. In
addition to skin tattoo marks, this guarantees the
achievement of a high reproducibility of patient posi-
tioning and accuracy of treatment delivery.
Afterwards these CT scans are used to outline organs
at risk (OARs) and to contour the clinical target volume
(CTV), which encompasses the metastatic vertebral
body and, with a margin of 1 cm, results in the planning
target volume (PTV). The target volume (=PTV) in each
treatment group consists of the entire metastatic verte-
bral body in a craniocaudal direction including the Proc.
costales et transversi to the right and left lateral sides.
In group A, treatment is being performed as intensity-
modulated radiotherapy (IMRT) and planned as either
tomotherapy, volumetric arc therapy (VMAT), or step-
and-shoot IMRT with daily cone-beam CT imaging for
rigid patient deformation during radiation. In group B ra-
diation is delivered by conventional, three-dimensional
(3D) planned, external beam radiotherapy in two to three
fields. Each group uses 6 MV photon energy plans with
multileaf collimator shaped radiation fields. A palliative
treatment regimen with a total prescribed dose of 30 Gy
in 3 Gy fraction doses and daily treatment sessions five
times per week is performed, with the 90% isodose sur-
rounding the PTV. OARs such as the skin, heart, or the
esophagus are delineated, and dose limit constraints are
prescribed to each of them following common consider-
ations according to QUANTEC parameters.
Data collection and follow-up period
During study observation, patient data are collected be-
fore the start of radiotherapy treatment (t0), at the end
of treatment (t1), and in the follow-up period at sched-
uled visits in our department at time points of 3 months
(t2) as well as 6 months (t3) after completion of treat-
ment (Figs. 1 and 2).
Patient clinical information is carefully documented in
case report forms (CRFs) using questionnaires, filled out
by each patient, that measure and quantify clinical symp-
toms and factors such as pain, radiation-induced side
effects and toxicity, as well as quality of life (European Or-
ganisation for Research and Treatment of Cancer Quality
of Life Questionnaire for patients with Bone Metastases
and for measure of Fatigue (EORTC BM22, FA13) and vis-
ual analog scale (VAS)). Furthermore, the follow-up re-
quirements include a CT scan 3 and 6 months after
completion of radiotherapy for evaluation of treatment re-
sponse, bone sclerosis, spinal stability, and possible com-
plications such as bone fractures.
Assessment of the primary and secondary endpoints
In this trial, radiation-induced toxicity 3 months after
completion ofpalliative radiotherapy will be evaluated as
the primary endpoint. Its extent is measured according
to criteria delineated by NCI Common Toxicity Criteria
for Adverse Events (CTCAE v 4.0).
Secondary endpoints will be bone re-calcification,
quality of life, spinal instability and fractures, local con-
trol, and clinical symptoms such as fatigue, pain relief,
or neurological deficits.
Statistical analysis and randomization
This trial is being performed as a pilot study; in the cal-
culation for statistical analysis a total of about 30 pa-
tients in each treatment group is considered an
appropriate sample size. Due to the explorative character
of this study, it is not possible to estimate the total num-
ber of cases. However, with a scheduled number of 30
patients per group, it will be possible to detect a
Fig. 2 Intervention and assessment schedule for IRON-1 trial
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standardized mean-value effect (Cohen’s d) of 0.8 with a
power of 80% and an alpha significance level of 5%. A
blocked randomization is used to allocate each partici-
pant into group A or B before start of treatment. All var-
iables were analyzed descriptively by tabulation of the
measures of the empirical distributions. According to the
scale level of the variables, means, standard deviations,
and medians as well as minimum and maximum or abso-
lute and relative frequencies, respectively, will be reported.
Additionally, for variables with longitudinal measure-
ments, the time courses of individual patients will be ana-
lyzed and summarized by treatment groups. Descriptive p
values of the corresponding statistical tests comparing the
treatment groups will be given. The Wilcoxon signed rank
test will be used to compare changes in group difference.
The Cohen’s effect size (ES) will be assessed for clinically
relevant change in questionnaire measures (<0.3 low, 0.3–
0.7 moderate, >0.7 strong difference). Moreover patient
data are collected in table form at the above-mentioned
time points for all completed questionnaires. All statistical
analyses will be performed with SAS software v 9.3 or
higher (SAS Institute, Cary, NC, USA).
Discussion
This prospective, single-center pilot trial performed at the
Department of Radiation Oncology at the University Hos-
pital of Heidelberg assesses radiation-induced toxicity 3
months after radiotherapy in patients with spinal bone
metastases by comparing intensity-modulated radiother-
apy versus conventional external beam radiotherapy. Espe-
cially in this palliative treatment setting a technical
approach to a limited extent of side effects and a higher
relief of symptoms is needed to result in higher quality of
life for palliative patients. Furthermore, this explorative
study analyzes the differences seen in bone sclerosis, qual-
ity of life, spinal stability, and local control as well as clin-
ical symptoms such as fatigue, pain relief, or neurological
deficits between the two treatment groups.
Trial status
Patient recruitment has not yet been completed.
Additional file
Additional file 1: SPIRIT 2013 checklist: recommended items to address
in a clinical trial protocol and related documents. (PDF 130 kb)
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